TherapeuticsMD (TXMD) Q4 2025 earnings summary

Executive summary

• Reported a net loss from continuing operations of $(0.7) million for 2025, improving by $1.7 million year-over-year.

• License revenue increased 71.6% to $3.0 million, primarily from the Mayne License Agreement.

• Operating expenses decreased by 5.9% to $7.4 million, mainly due to lower impairment charges.

• Cash and cash equivalents stood at $7.5 million as of December 31, 2025.

Outlook and guidance

• Actively evaluating strategic alternatives, including potential acquisitions, mergers, or asset sales, with no set timetable for completion.

• No further updates on strategic review will be provided unless deemed necessary.

Key financial ratios and metrics

• Net loss per basic and diluted share improved to $(0.06) from $(0.20) year-over-year.

• License revenue growth of $1.3 million year-over-year.